India
· Delayed Price · Currency is INR NATCO Pharma Statistics
Total Valuation
NATCO Pharma has a market cap or net worth of INR 156.62 billion. The enterprise value is 134.50 billion.
| Market Cap | 156.62B |
| Enterprise Value | 134.50B |
Important Dates
The last earnings date was Tuesday, August 12, 2025.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | Aug 19, 2025 |
Share Statistics
| Current Share Class | 179.11M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.00% |
| Shares Change (QoQ) | -0.01% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 81.33M |
Valuation Ratios
The trailing PE ratio is 9.23 and the forward PE ratio is 13.79.
| PE Ratio | 9.23 |
| Forward PE | 13.79 |
| PS Ratio | 3.56 |
| PB Ratio | 2.06 |
| P/TBV Ratio | 2.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 7.92 |
| EV / Sales | 3.06 |
| EV / EBITDA | 6.85 |
| EV / EBIT | 7.85 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.04 |
| Debt / EBITDA | 0.14 |
| Debt / FCF | n/a |
| Interest Coverage | 78.24 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 15.17% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 10.95M |
| Profits Per Employee | 4.23M |
| Employee Count | 4,016 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NATCO Pharma has paid 3.65 billion in taxes.
| Income Tax | 3.65B |
| Effective Tax Rate | 17.70% |
Stock Price Statistics
The stock price has decreased by -38.72% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -38.72% |
| 50-Day Moving Average | 938.32 |
| 200-Day Moving Average | 1,052.48 |
| Relative Strength Index (RSI) | 37.56 |
| Average Volume (20 Days) | 71,078 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NATCO Pharma had revenue of INR 43.96 billion and earned 16.98 billion in profits. Earnings per share was 94.78.
| Revenue | 43.96B |
| Gross Profit | 36.53B |
| Operating Income | 17.14B |
| Pretax Income | 20.60B |
| Net Income | 16.98B |
| EBITDA | 19.63B |
| EBIT | 17.14B |
| Earnings Per Share (EPS) | 94.78 |
Balance Sheet
The company has 24.97 billion in cash and 2.79 billion in debt, giving a net cash position of 22.17 billion.
| Cash & Cash Equivalents | 24.97B |
| Total Debt | 2.79B |
| Net Cash | 22.17B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 76.12B |
| Book Value Per Share | 424.69 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 83.11%, with operating and profit margins of 38.98% and 38.62%.
| Gross Margin | 83.11% |
| Operating Margin | 38.98% |
| Pretax Margin | 46.86% |
| Profit Margin | 38.62% |
| EBITDA Margin | 44.64% |
| EBIT Margin | 38.98% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 8.00, which amounts to a dividend yield of 0.89%.
| Dividend Per Share | 8.00 |
| Dividend Yield | 0.89% |
| Dividend Growth (YoY) | -9.09% |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.00% |
| Shareholder Yield | 0.89% |
| Earnings Yield | 10.84% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 26, 2015. It was a forward split with a ratio of 5.
| Last Split Date | Nov 26, 2015 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |